The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

The present invention relates to a purified pollen particle that retains its intine and of exine layer and comprises nanosystems, to compositions including same, and to uses thereof.

Microcapsules with a plurality of functionalities on the surface, an article of manufacture including microcapsules with a plurality of functionalities on the surface, and a method of forming a microcapsule with a plurality of functionalities on the surface which includes: providing one or more microcapsules; forming one or more wax particles, the wax particles including a wax core with the one or more microcapsules partially embedded in the wax core; functionalizing a first exposed surface of the one or more microcapsules; removing the functionalized one or more microcapsules from the wax core; and functionalizing a second exposed surface of the functionalized one or more microcapsules, the second exposed surface previously embedded in the wax core are disclosed.

Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics.

A probiotic microcapsule for the treatment of reproductive tract infection and a preparation method and application thereof are provided. The probiotic microcapsule is obtained by coating probiotics with the coating material. The probiotics include one or several of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus crimpus, Lactobacillus brevis, Lactobacillus salivary, Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus bulgaricus. As probiotics screened in reproductive tract, it has high safety; It endows probiotics with adhesion function to ensure their effect in the reproductive tract; It overcomes the defects of current antibiotic therapy; It is expected to be used in a variety of reproductive tract infectious diseases.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

The present invention relates to hybrid microcapsules, with a hydrophobic material-based core, preferably a perfume, and a polymeric shell comprising lignin particles. Process for preparing said microcapsules is also an object of the invention. Perfuming compositions and consumer products comprising said microcapsules, in particular perfumed consumer products in the form of home care or personal care products, are also part of the invention.

The invention is directed to a microcapsule and the method to obtain it. The microcapsule comprises a core in the form of a lipid sphere coated by a protein film, wherein the lipid sphere comprises sporulated microorganisms and at least one lipid wall material, and the protein film is a mix of carbohydrate, protein material and water. The method to obtain this microcapsule includes the stages of mixing sphere components, mixing protein film components, homogenizing the protein film and the subsequent coating of the lipid sphere by means of fluidization with the protein film.

The present disclosure relates to a taste-masking microcapsule composition. The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.

Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.